Unum Therapeutics, Inc.
(NASDAQ : UMRX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc. 4.19%75.901.0%$2173.16m
AMGNAmgen, Inc. 4.32%206.831.3%$952.15m
REGNRegeneron Pharmaceuticals, Inc. 5.45%474.002.6%$817.78m
BIIBBiogen, Inc. 8.03%320.571.5%$769.00m
MRNAModerna, Inc. 0.73%30.270.0%$644.89m
VRTXVertex Pharmaceuticals, Inc. 5.53%229.251.9%$556.02m
ILMNIllumina, Inc. 1.33%272.623.5%$489.08m
ALXNAlexion Pharmaceuticals, Inc. 3.67%87.092.0%$275.51m
AAgilent Technologies, Inc. 2.25%72.321.6%$241.82m
EXASEXACT Sciences Corp. 1.47%58.7521.0%$208.48m
INCYIncyte Corp. 3.57%71.422.5%$173.52m
SGENSeattle Genetics, Inc. 5.54%115.326.1%$171.27m
BMRNBioMarin Pharmaceutical, Inc. 3.10%81.984.3%$165.33m
NVAXNovavax, Inc. 9.58%14.30114.7%$164.32m
CODXCo-Diagnostics, Inc. -10.60%8.180.0%$132.76m

Company Profile

Unum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.